Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.

The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

People discussed their intense hair loss treatments, including the use of dutasteride, RU58841, minoxidil, tretinoin, essential oils, microneedling, and various topical sprays. Some users reported success with these methods in preventing hair loss and stimulating hair growth.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses various treatments for hair loss, including finasteride, minoxidil, dutasteride, microneedling, and checking for nutrient deficiencies. Some users suggest adding hydrocortisone butyrate, low-dose progesterone, or tretinoin to treatment regimens, while others recommend cosmetic solutions like Toppik hair fibers or shaving the head.

A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

A user's hair loss progress after 4 months of using a topical fin and min mix, with responses from other users about their experience with the same treatments.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

RU58841 powder may degrade over time, even when stored in a freezer. Users discuss its potential effectiveness after three years of storage.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

The conclusion of this conversation about hair loss is that the user, y00sh420, tried various treatments including a $700 lllt helmet, topical minoxidil and finasteride, spectraDNC, and micro needling, but did not achieve the desired results. They have decided to stop trying until a cure for male pattern baldness is found. Other users expressed different opinions on hair loss treatments.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.